HK1244201A1 - 芋螺毒素(conotoxin)肽的修饰和用途 - Google Patents
芋螺毒素(conotoxin)肽的修饰和用途 Download PDFInfo
- Publication number
- HK1244201A1 HK1244201A1 HK18103429.5A HK18103429A HK1244201A1 HK 1244201 A1 HK1244201 A1 HK 1244201A1 HK 18103429 A HK18103429 A HK 18103429A HK 1244201 A1 HK1244201 A1 HK 1244201A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pain
- conotoxin peptides
- modifications
- rgia
- conotoxin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Insects & Arthropods (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462123123P | 2014-11-07 | 2014-11-07 | |
| US201462123123P | 2014-11-07 | ||
| PCT/US2015/059613 WO2016073949A1 (en) | 2014-11-07 | 2015-11-06 | Modifications and uses of conotoxin peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1244201A1 true HK1244201A1 (zh) | 2018-08-03 |
Family
ID=55909927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18103429.5A HK1244201A1 (zh) | 2014-11-07 | 2015-11-06 | 芋螺毒素(conotoxin)肽的修饰和用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11014970B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3215172B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6798998B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102623475B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107249616A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015342767B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2966865C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2950901T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1244201A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL284236B2 (cg-RX-API-DMAC7.html) |
| TW (2) | TWI708790B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016073949A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107249616A (zh) | 2014-11-07 | 2017-10-13 | 奇尼塔慢性疼痛有限责任公司 | 芋螺毒素(conotoxin)肽的修饰和用途 |
| RU2731217C2 (ru) * | 2016-11-28 | 2020-08-31 | Общество с ограниченной ответственностью "Синейро" | Аналог альфа-конотоксина RgIA для лечения боли |
| US10947274B1 (en) * | 2018-05-01 | 2021-03-16 | University Of Utah Research Foundation | Synthetic analgesic peptides of RgIA analogs |
| KR102117106B1 (ko) | 2018-09-14 | 2020-06-01 | 대한민국(환경부 국립생물자원관장) | N형 칼슘채널 차단 활성을 갖는 긴호랑거미 유래 알지신-ⅰ 펩타이드 및 이의 용도 |
| WO2020142102A1 (en) * | 2019-01-04 | 2020-07-09 | Kineta Chronic Pain, Llc | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions |
| US11612661B2 (en) | 2019-01-04 | 2023-03-28 | Kineta Chronic Pain, Llc | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions |
| CN115702161A (zh) * | 2020-04-09 | 2023-02-14 | 格罗制药公司 | 抑制烟碱乙酰胆碱受体活性的肽组合物和方法 |
| KR20230031884A (ko) * | 2020-06-03 | 2023-03-07 | 유타대학연구재단 | 형태적으로 제약된 α-RGIA 유사체 |
| CN114805492B (zh) * | 2022-03-15 | 2025-07-22 | 上海元炘执药科技有限公司 | 一种用于抑制电压门控钠离子通道1.4的芋螺毒素kiiia突变体及其制备方法和应用 |
| CN115286700B (zh) * | 2022-08-22 | 2024-11-19 | 中国海洋大学 | 一种具有血浆稳定性的镇痛多肽 |
| CN118184744A (zh) * | 2024-03-29 | 2024-06-14 | 广西大学 | 一种靶向神经型乙酰胆碱受体的多肽分子及其制备方法和应用 |
| CN119912549A (zh) * | 2024-12-29 | 2025-05-02 | 中国人民解放军军事科学院防化研究院 | 一类脂肪醛修饰的芋螺肽及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595972A (en) | 1993-06-29 | 1997-01-21 | University Of Utah Research Foundation | Conotoxin peptides |
| US6797808B1 (en) | 1999-01-29 | 2004-09-28 | University Of Utah Research Foundation | α-conotoxin peptides |
| JP2003512388A (ja) * | 1999-10-18 | 2003-04-02 | アクゾ・ノベル・エヌ・ベー | 免疫治療で使用される修飾ペプチドおよびペプチド模倣体 |
| WO2004050688A1 (en) | 2002-12-02 | 2004-06-17 | Xenome Ltd | NOVEL χ-CONOTOXIN PEPTIDES (-II) |
| US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| EP1770099A1 (en) * | 2005-09-28 | 2007-04-04 | University of Geneva | Method of producing a modified (poly)peptide |
| US7745573B2 (en) | 2006-02-17 | 2010-06-29 | Polychip Pharmaceuticals Pty Ltd. | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides |
| EP1834962A1 (de) * | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| CA2566832A1 (en) * | 2006-04-13 | 2007-10-13 | The University Of Queensland | Cyclised alpha-conotoxin peptides |
| US9284358B2 (en) * | 2006-07-18 | 2016-03-15 | University Of Utah Research Foundation | Conotoxin peptides |
| JP5840345B2 (ja) * | 2006-09-08 | 2016-01-06 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 修飾ヒト血漿ポリペプチドまたは修飾ヒトＦｃ足場タンパク質ならびにこれらの利用 |
| WO2009126292A2 (en) * | 2008-04-08 | 2009-10-15 | Aileron Therapeutics, Inc. | Biologically active peptidomimetic macrocycles |
| DE102009050885A1 (de) * | 2009-10-27 | 2011-04-28 | Behr Gmbh & Co. Kg | Luftausströmer |
| CA2913993A1 (en) * | 2013-05-31 | 2014-12-04 | University Of Utah Research Foundation | Conotoxin peptides, pharmaceutical compositions and uses thereof |
| CN107249616A (zh) | 2014-11-07 | 2017-10-13 | 奇尼塔慢性疼痛有限责任公司 | 芋螺毒素(conotoxin)肽的修饰和用途 |
| US11612661B2 (en) | 2019-01-04 | 2023-03-28 | Kineta Chronic Pain, Llc | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions |
-
2015
- 2015-11-06 CN CN201580068468.7A patent/CN107249616A/zh active Pending
- 2015-11-06 WO PCT/US2015/059613 patent/WO2016073949A1/en not_active Ceased
- 2015-11-06 ES ES15856496T patent/ES2950901T3/es active Active
- 2015-11-06 KR KR1020177015279A patent/KR102623475B1/ko active Active
- 2015-11-06 US US15/525,024 patent/US11014970B2/en active Active
- 2015-11-06 JP JP2017544555A patent/JP6798998B2/ja active Active
- 2015-11-06 TW TW104136722A patent/TWI708790B/zh not_active IP Right Cessation
- 2015-11-06 IL IL284236A patent/IL284236B2/en unknown
- 2015-11-06 EP EP15856496.3A patent/EP3215172B1/en active Active
- 2015-11-06 AU AU2015342767A patent/AU2015342767B2/en active Active
- 2015-11-06 TW TW109134130A patent/TWI777260B/zh not_active IP Right Cessation
- 2015-11-06 CA CA2966865A patent/CA2966865C/en active Active
- 2015-11-06 HK HK18103429.5A patent/HK1244201A1/zh unknown
-
2017
- 2017-05-07 IL IL252152A patent/IL252152B/en unknown
-
2020
- 2020-03-10 JP JP2020040876A patent/JP2020090550A/ja not_active Withdrawn
- 2020-09-29 US US17/037,521 patent/US11618772B2/en active Active
-
2021
- 2021-08-03 AU AU2021212006A patent/AU2021212006B2/en active Active
-
2022
- 2022-01-26 JP JP2022010036A patent/JP2022063872A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL252152B (en) | 2021-07-29 |
| KR20170083574A (ko) | 2017-07-18 |
| ES2950901T3 (es) | 2023-10-16 |
| EP3215172A1 (en) | 2017-09-13 |
| TWI777260B (zh) | 2022-09-11 |
| JP2022063872A (ja) | 2022-04-22 |
| AU2021212006B2 (en) | 2023-08-31 |
| KR102623475B1 (ko) | 2024-01-09 |
| CA2966865C (en) | 2023-03-21 |
| TW202120525A (zh) | 2021-06-01 |
| IL252152A0 (en) | 2017-07-31 |
| US11014970B2 (en) | 2021-05-25 |
| US20180362599A1 (en) | 2018-12-20 |
| AU2015342767B2 (en) | 2021-05-13 |
| JP2020090550A (ja) | 2020-06-11 |
| IL284236B2 (en) | 2023-04-01 |
| AU2021212006A1 (en) | 2021-08-26 |
| EP3215172B1 (en) | 2023-04-26 |
| JP2018500385A (ja) | 2018-01-11 |
| EP3215172A4 (en) | 2018-07-25 |
| CA2966865A1 (en) | 2016-05-12 |
| JP6798998B2 (ja) | 2020-12-09 |
| TWI708790B (zh) | 2020-11-01 |
| TW201629085A (zh) | 2016-08-16 |
| WO2016073949A1 (en) | 2016-05-12 |
| IL284236B (en) | 2022-12-01 |
| US11618772B2 (en) | 2023-04-04 |
| CN107249616A (zh) | 2017-10-13 |
| AU2015342767A1 (en) | 2017-06-15 |
| US20210122792A1 (en) | 2021-04-29 |
| IL284236A (en) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1244201A1 (zh) | 芋螺毒素(conotoxin)肽的修饰和用途 | |
| ZA202004557B (en) | Modulatory polynucleotides | |
| MX2023010042A (es) | Polinucleotidos moduladores. | |
| WO2016149613A3 (en) | Selective mcl-1 binding peptides | |
| WO2016011306A3 (en) | Terminal modifications of polynucleotides | |
| SG10202001831SA (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
| WO2016170348A3 (en) | Sarna compositions and methods of use | |
| MX2017009595A (es) | Compuestos antisenescentes y usos de los mismos. | |
| PH12018501114A1 (en) | Polypeptides inhibiting cd40l | |
| PL3515420T3 (pl) | Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek | |
| ZA201806844B (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
| WO2017075349A3 (en) | Selective mcl-1 binding peptides | |
| HK1221425A1 (zh) | 芋螺毒素(conotoxin)肽，其医药组合物和用途 | |
| HK1251481A1 (zh) | 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 | |
| WO2015187521A3 (en) | Anti-blys antibodies | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| HK1256033A1 (zh) | 用於刺激免疫系统的肽 | |
| PH12017500853A1 (en) | Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases | |
| MX2017010883A (es) | Composicion para el tratamiento de la infertilidad. | |
| MX2017003216A (es) | Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. | |
| HK1254231A1 (zh) | 米托-和厚朴酚化合物及其合成方法和用途 | |
| GB2546439B (en) | Ezrin-derived peptides and pharmaceutical compositions thereof | |
| MX2017006513A (es) | Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor. | |
| GB201518456D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases | |
| EP3399990A4 (en) | THERAPEUTIC COMPOSITIONS WITH PEPTIDES AND USES THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHRG | Changes in the register |
Free format text: IADONATO, SHAWN, P Free format text: POSAKONY, JEFFREY JERARD |